Sodium–Glucose Cotransporter 2 Inhibitors as Potential Antioxidant Therapeutic Agents in Cardiovascular and Renal Diseases
Redox (reduction–oxidation) imbalance is a physiological feature regulated by a well-maintained equilibrium between reactive oxygen species (ROS) and oxidative stress (OS), the defense system of the body (antioxidant enzymes). The redox system comprises regulated levels of ROS in the cells, tissues...
Saved in:
| Main Authors: | Tapan A. Patel, Hong Zheng, Kaushik P. Patel |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Antioxidants |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3921/14/3/336 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effect of Sodium-Glucose Cotransporter Type 2 Inhibitors on The Development and Course of Atrial Fibrillation
by: D. A. Ishmaev, et al.
Published: (2025-01-01) -
Role of sodium-glucose cotransporter 2 inhibitors in cardiovascular events in patients with heart failure
by: Eva Muja, et al.
Published: (2025-07-01) -
Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Calcium Homeostasis: Where We Stand Now
by: Alessandro Cuttone, et al.
Published: (2025-05-01) -
Sodium–Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction
by: Nicia I. Profili, et al.
Published: (2025-03-01) -
Efficacy and Safety of Bexagliflozin, a Selective Sodium-Glucose Cotransporter-2 Inhibitor, in Type 2 Diabetes: A Systematic Review and Meta-Analysis
by: A.B.M. Kamrul-Hasan, et al.
Published: (2025-01-01)